NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias

Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambello, Renato, Barilà, Gregorio, Manni, Sabrina, Piazza, Francesco, Semenzato, Gianpietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140687/
https://www.ncbi.nlm.nih.gov/pubmed/32245149
http://dx.doi.org/10.3390/cells9030768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140687/
https://www.ncbi.nlm.nih.gov/pubmed/32245149
http://dx.doi.org/10.3390/cells9030768

Ejemplares similares